Q4 2025 Nutex Health Inc Earnings Call Transcript

Mar 06, 2026 / 03:30PM GMT

Release Date Price: €62.5 (-32.80%)

Transcript 8-K10-K

Key Points

Positve

Nutex Health Inc (NUTX) reported a significant revenue increase of 82% for the full year 2025, reaching $875.3 million compared to $479.9 million in 2024.
Net income rose to $70.8 million in 2025 from $52.1 million in 2024, showcasing strong financial performance.
The company successfully opened three new hospitals in 2025 and early 2026, demonstrating its expansion capabilities.
Nutex Health Inc (NUTX) improved its cash position significantly, with cash on hand increasing to $186 million by the end of 2025, up from $41 million a year earlier.
The company achieved a high patient satisfaction rating, with over 8,700 reviews averaging 4.8 out of 5, highlighting its commitment to quality care.

Negative

Nutex Health Inc (NUTX) faced a one-time $55 million revenue reduction in Q4 2025 due to arbitration claims deemed ineligible, impacting quarterly financial results.
The company's total revenue for Q4 2025 decreased by 41.1% compared to the same quarter in 2024, primarily due to the arbitration true-up.
Despite the overall annual revenue growth, the Population Health division saw only a slight revenue increase of 0.7% in 2025.
The arbitration process remains costly, with arbitration-related expenses accounting for approximately 26% of arbitration-related revenue.
The company experienced a decrease in operating income for Q4 2025, down to $30.9 million from $114 million in Q4 2024, reflecting the impact of the arbitration adjustments.

Operator

Greetings. Welcome to Nutex Health's fourth-quarter and full-year 2025 10-K earnings call. (Operator Instructions)

Please note, this conference is being recorded. At this time, I'll now turn the conference over to Jennifer Rodriguez, Investor Relations Manager. Thank you, Jennifer. You may now begin.

Jennifer Rodriguez

Nutex Health Inc - Investor Relations

Good morning, everyone, and welcome to Nutex Health, Inc.'s fourth-quarter and full-year 2025 earnings call. My name is Jennifer Rodriguez, and I'm happy to serve as your moderator today. We're truly grateful for your participation and your continued interest in our company as we share the highlights of another exceptional year. Please note that this call is being recorded for future reference.

Joining me this morning are some of the key leaders driving Nutex Health forward: our Chairman and CEO, Dr. Tom Vo; our Chief Financial Officer, Jon Bates; our President, Dr. Warren Hosseinion; and our Chief Operating Officer, Wes Bamburg. Together, they'll provide prepared remarks to give you a

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.